Sisram Medical Partners with Sinmait Medical Technology to Build Next-Generation Manufacturing and Innovation Hub in China

Core Insights - Sisram Medical Ltd has entered into a memorandum of understanding with Sinmait Medical Technology to enhance localization efforts in China, which is expected to accelerate its strategic implementation and business expansion in the Chinese market [1][2]. Group 1: Partnership and Localization - The partnership with Fosun Pharma will allow Sisram to leverage advanced production capabilities and local expertise to establish a manufacturing hub in China, initially focusing on Energy-Based Devices (EBD) [3]. - The new facility will cater to domestic demand and serve as a strategic center for the APAC region, addressing the growing need for scalable production and advanced research and development [4]. Group 2: Strategic Vision and Market Position - The collaboration elevates Sisram's localization strategy in China, aiming to build a comprehensive and competitive localized ecosystem, which is a key milestone in the company's vision of "In China, for Global" [5]. - The synergistic development and localized manufacturing of EBD alongside other product offerings will enhance the portfolio's effectiveness, providing Chinese consumers with superior and accessible domestic wellness solutions [5]. Group 3: Company Overview - Sisram Medical Ltd is a global leader in medical aesthetic solutions with over 25 years of expertise in Energy-Based Devices (EBD), serving customers in over 110 countries and regions [6]. - The company has been listed on the Main Board of the Hong Kong Stock Exchange since September 2017 and is majority-owned by Fosun Pharma [6].